Physician profile
Daniel Ortiz
NPI 1487929584
$7,144.42
in general payments reported to CMS, 2019-2025
26 companies · $476 in 2025
The $476 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,676 · 2020: $1,399 · 2021: $901 · 2022: $263 · 2023: $1,951 · 2024: $479 · 2025: $476.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,831 · Travel and Lodging: $1,000 · Debt Forgiveness: $74.48.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,831.41 |
| Travel and Lodging | $999.96 |
| Debt Forgiveness | $74.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $1,542.68 | 2020-2025 | Impella |
| Inari Medical, INC. | $1,353.27 | 2023 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Abbott Laboratories | $1,153.58 | 2019-2021 | |
| Penumbra, INC. | $1,099.92 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $412.97 | 2022-2025 | Camzyos, Eliquis |
| Janssen Pharmaceuticals, INC | $193.61 | 2019-2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $175.05 | 2021-2024 | |
| Cardiovascular Systems INC. | $166.87 | 2020 | |
| Biocompatibles, INC. | $123.69 | 2019 | |
| Merck Sharp & Dohme LLC | $115.03 | 2022-2025 | Verquvo |
| Boston Scientific Corporation | $103.03 | 2022-2025 | Lux-Dx Insertable Cardiac Monitor |
| Medtronic Vascular, INC. | $91.89 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $81.94 | 2023-2025 | Jardiance |
| Baxter Healthcare | $74.48 | 2025 | |
| Bard Peripheral Vascular, INC. | $71.99 | 2020-2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $66.51 | 2022-2025 | |
| Philips North America LLC | $58.30 | 2024 | (5091) Amb Mon & Diag Und |
| Becton, Dickinson and Company | $50.50 | 2023-2024 | |
| Lexicon Pharmaceuticals, INC. | $46.73 | 2023-2024 | Inpefa |
| Novo Nordisk INC | $36.28 | 2020-2025 | Wegovy |
| Amarin Pharma, INC. | $35.32 | 2019-2020 | |
| Chiesi USA, INC. | $22.45 | 2022 | |
| Inspire Medical Systems, INC. | $22.18 | 2024 | Inspire |
| Esperion Therapeutics, INC. | $15.88 | 2021 | |
| Kiniksa Pharmaceuticals International, Plc | $15.27 | 2024 | Arcalyst |
| Amgen INC. | $15.00 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Ortiz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.